Toggle Offcanvas
...
 
Dasatinib Tenders

Dasatinib Tenders

View Dasatinib tenders, RFPs and contracts. Bid on readily available Dasatinib tenders with the best and most comprehensive tendering platform, since 2002.
Dasatinib is a targeted therapy used in chronic myeloid leukemia CML and certain types of acute lymphoblastic leukemia ALL . It works by blocking specific proteins called tyrosine kinases that promote cancer cell growth.

Bidding for Dasatinib tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Dasatinib.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Dasatinib market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Dasatinib tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

6 Live Notices for Dasatinib Tenders

Showing 1 to 6

Dasatinib And Placebo Medication Supply (Matodextrin) For The Development Of Phase Ii Clinical Trial Financed By The Mpy 110/25 Project
country Spain
posting date30 May 2025
deadline20 Jun 2025
Joint Purchase Dasatinib 50 And 70 Mg Cm Rec 1000021245
country Chile
posting date27 May 2025
deadline27 Jun 2025
Medicines Contracts With Accession Option
country Germany
posting date20 May 2025
deadline01 Aug 2025
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dasatinib (Excl. Strength 100 Mg In Standard Sizes N2 And N3, Atc L01Ea02 For The Period 01.11.24 - 31.10.26
country Germany
posting date17 Sep 2024
deadline05 Sep 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dasatinib (Excl. Strength 100 Mg In Standard Sizes N2 And N3, Atc L01Ea02 For The Period 01.11.24 - 31.10.26
country Germany
posting date17 Sep 2024
deadline05 Sep 2026
Tab Dasatinib 100 Mg
country India
posting date27 May 2025
deadline12 Jun 2025

Share Share this page